Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma

The cure rate of osteosarcoma has not improved in the past 30 years. The search for new treatments and drugs is urgently needed. Apatinib is a high selectivity inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, exerting promising antitumoral effect in various tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kuisheng, Ren, Tingting, Huang, Yi, Sun, Kunkun, Bao, Xing, Wang, Shidong, Zheng, Bingxin, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596600/
https://www.ncbi.nlm.nih.gov/pubmed/28837148
http://dx.doi.org/10.1038/cddis.2017.422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596600/
https://www.ncbi.nlm.nih.gov/pubmed/28837148
http://dx.doi.org/10.1038/cddis.2017.422

Ejemplares similares